CGRP Medications for Migraine: What Dysautonomia Patients Need to Know

Calcitonin gene-related peptide (CGRP) inhibitors represent the first class of migraine-specific preventive medications ever developed, and they have transformed migraine management since their FDA approval beginning in 2018. For dysautonomia patients — who carry a disproportionate migraine burden — understanding how these medications work, which ones are available, and what the specific considerations are for POTS, MCAS, and EDS is essential for making informed treatment decisions.

What Is CGRP and Why Does It Matter?

CGRP is a 37-amino-acid neuropeptide released from trigeminal nerve endings during migraine attacks. It is one of the most potent vasodilators in the human body, and its release in the meninges triggers the neuroinflammatory cascade responsible for migraine pain. CGRP also plays roles in cardiovascular regulation, pain transmission, and — critically for dysautonomia patients — autonomic function.

CGRP receptors are found throughout the cardiovascular system, including in the heart, blood vessels, and autonomic ganglia. CGRP promotes vasodilation and modulates sympathetic tone. This dual role in both migraine and autonomic function is why CGRP inhibition has implications beyond headache for dysautonomia patients.

Available CGRP Medications

There are two classes of CGRP-targeting medications:

Monoclonal antibodies (preventive, monthly or quarterly dosing):

Small molecule CGRP receptor antagonists — gepants (acute and preventive):

Efficacy in Migraine

The monoclonal antibodies reduce monthly migraine days by approximately 50% in 50% of patients — a meaningful improvement over older preventives. Approximately 25–30% of patients achieve a ≥75% reduction. The gepants are effective for acute treatment and, in the case of rimegepant and atogepant, for prevention as well.

For vestibular migraine specifically, the evidence is less robust (most trials excluded VM patients), but clinical experience and case series suggest similar efficacy to episodic migraine.

Specific Considerations for POTS Patients

Cardiovascular effects. Because CGRP is a vasodilator, blocking it theoretically could increase vascular resistance and worsen orthostatic hypertension in hyperadrenergic POTS patients. In practice, most POTS patients tolerate CGRP inhibitors well, and some report improved orthostatic tolerance — possibly because reducing neuroinflammation and central sensitization improves overall autonomic stability. However, patients with hyperadrenergic POTS should monitor blood pressure carefully when starting these medications.

Constipation. Erenumab (Aimovig) has a notably higher rate of constipation than other CGRP antibodies — approximately 3–4% vs. < 1% for the ligand-targeting antibodies. For gastroparesis patients, this is a significant concern. Fremanezumab, galcanezumab, or eptinezumab are preferable in patients with GI motility issues.

Injection site reactions. All subcutaneous CGRP antibodies can cause injection site reactions. In MCAS patients, these reactions may be more pronounced. Pre-treating with antihistamines before injection and rotating injection sites can help.

Drug interactions. The gepants are metabolized by CYP3A4 and are sensitive to strong CYP3A4 inhibitors (azole antifungals, some antiretrovirals) and inducers (rifampin, carbamazepine). This is relevant for MCAS patients on ketotifen or other CYP3A4-metabolized medications.

Specific Considerations for MCAS Patients

CGRP has direct effects on mast cell degranulation — it can trigger mast cell activation in some contexts. Paradoxically, blocking CGRP may reduce mast cell-mediated neuroinflammation, which is why some MCAS patients report improvement in both migraine and mast cell symptoms on CGRP inhibitors.

However, the monoclonal antibodies themselves can trigger mast cell reactions in sensitized patients. Starting with a lower dose (70 mg erenumab rather than 140 mg) or choosing eptinezumab (IV, with controlled infusion rate) may reduce this risk. Premedication with antihistamines is reasonable.

Specific Considerations for EDS/hEDS Patients

EDS patients have a higher prevalence of both migraine and craniocervical instability. If CCI is contributing to migraine (through vertebral artery compression or brainstem irritation), CGRP inhibitors will provide limited benefit until the structural issue is addressed. A neurosurgeon experienced in CCI should evaluate patients with EDS and refractory migraine before escalating to CGRP biologics.

How to Access CGRP Medications

All CGRP monoclonal antibodies require a prescription from a neurologist or headache specialist. They are expensive (approximately $600–900/month list price) but most manufacturers offer patient assistance programs. Insurance coverage has improved significantly since 2018, and most plans cover at least one CGRP antibody after failure of two or more older preventives (typically topiramate, valproate, amitriptyline, or a beta-blocker).

The gepants (rimegepant, ubrogepant, atogepant) are available through most pharmacies with a prescription and are generally covered by insurance for patients who have failed triptans.

Practical Starting Point

For most dysautonomia patients with migraine, the recommended sequence is:

1. Optimize POTS management first — many migraines improve with better orthostatic control.
2. If migraine persists, try a beta-blocker (propranolol or metoprolol) — these treat both conditions.
3. If beta-blockers are insufficient or not tolerated, add a CGRP antibody. Fremanezumab or galcanezumab are preferred over erenumab in patients with GI issues.
4. For acute treatment, rimegepant is preferred over triptans in patients with cardiovascular concerns (triptans are vasoconstrictors and are relatively contraindicated in some POTS subtypes).

The ChatDys Treatments page includes CGRP medications in the migraine category, and the AI can help you track migraine frequency and identify patterns that correlate with your POTS symptoms.